ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting



    TORONTO, Feb. 26 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that five abstracts have been selected for presentation at the
American Association for Cancer Research (AACR) Annual Meeting held from April
12-16, 2008 in San Diego, California. The Company will deliver presentations
that will disclose new findings about its CD44, TROP-2, CD59, and CD9 antibody
programs.
    "The inclusion of five ARIUS abstracts in this conference is a
significant achievement, demonstrating the scientific community's interest in
our programs and the high quality of our research," said Dr. David Young,
President and CEO. "Among these abstracts are findings from our cancer stem
cell programs targeting CD44 and CD9. This is an exciting new area of cancer
research and as we prepare our CD44 antibody to enter human clinical trials
this year, we believe we will have one of the only novel cancer stem cell
drugs entering clinical trials in the near-term."

    The following ARIUS' abstracts will be presented:

    Abstract Number 3975:
    "Preclinical development of huARH460-16-2, a humanized antibody to the
CD44 cancer stem cell target." Experimental and Molecular Therapeutics 32,
Tuesday, April 15, 2008, 8:00 AM

    Abstract Number 3976:
    "Anti-CD44 antibody, ARH460-16-2, binds to human AML CD34+CD38- cancer
stem cells and demonstrates anti-tumor activity in an AML xenograft model."
Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

    Abstract Number 3990:
    "AR47A6.4.2, a naked monoclonal antibody targeting Trop-2, exhibits
anti-tumor efficacy in multiple human cancer models as a monotherapeutic agent
and demonstrates efficacy in combination therapy." Experimental and Molecular
Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

    Abstract Number 3993:
    "Anti-CD9 antibody, AR40A746.2.3, inhibits tumor growth in pancreatic and
breast cancer models and recognizes CD9 on CD34+CD38- leukemic cancer stem
cells." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008,
8:00 AM

    Abstract Number 3995:
    "A monoclonal antibody targeting CD59 (AR36A36.11.1), enhances complement
activity and exhibits potent in vivo efficacy in multiple human cancer
models." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008,
8:00 AM

    About ARIUS

    ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than 500
antibody candidates. In addition to the antibodies it is developing in-house,
ARIUS has ongoing partnerships with key biotechnology and drug development
companies. ARIUS is listed on the TSX under the symbol "ARI". For further
information, visit www.ariusresearch.com

    Forward-Looking Statements

    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

    %SEDAR: 00013708E




For further information:

For further information: Warren Whitehead, C.M.A., Chief Financial
Officer, ARIUS Research Inc., (416) 862-2323 ext. 214,
wwhitehead@ariusresearch.com, contact@ariusresearch.com; James Smith, Investor
Relations, (416) 815-0700 ext. 229, jsmith@equicomgroup.com

Organization Profile

ARIUS RESEARCH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890